
- AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects.
- ABBV is trading at fresh all-time highs.
- Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages.
- Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside.